Johnson & Johnson Research and development expense percent to sales decreased by 3.9% to 14.7% in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 14.7% to 14.7%.
other_research_and_development_expense_excluding_acquire_a21938| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 14.6% | 14.7% | 14.8% | 15.4% | 17.4% | 16.6% | 17.2% | 16.2% | 16.6% | 15.3% | 22% | 14.7% | 14.8% | 15.3% | 14.7% |
| QoQ Change | — | +0.7% | +0.7% | +4.1% | +13.0% | -4.6% | +3.6% | -5.8% | +2.5% | -7.8% | +43.8% | -33.2% | +0.7% | +3.4% | -3.9% |
| YoY Change | — | — | — | +5.5% | +18.4% | +12.2% | +11.7% | -6.9% | +0.0% | -11.0% | +35.8% | -11.4% | -3.3% | -30.5% | +0.0% |